Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock Price Today
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Bitcoin trades just $200 above Strategy's average cost, risking losses for MSTR if BTC closes below $75,451.
Strategy Inc. holds 849,327 Bitcoin at an average cost of $75,451, with Bitcoin currently trading slightly above this level at $75,662. If Bitcoin closes below this average cost, Strategy would record significant unrealized losses impacting MSTR's fi...
JPMorgan Income ETF (JPIE) rated Buy for its strong income and controlled risk amid high inflation and rates.
The JPMorgan Income ETF (JPIE) is recommended as a Buy due to its focus on securitized assets, which currently offer better premiums than corporate bonds. The ETF is expected to provide high income with a controlled risk profile, making it a solid ch...
$1,000 invested in ADP 10 years ago grew to $4,147 with dividends reinvested, outpacing the S&P 500.
ADP's dual income from payroll fees and investing client payroll funds helped it grow steadily over the past decade. A $1,000 investment in ADP in 2016 would be worth $4,147 today with dividends reinvested, outperforming the S&P 500's 243% return. De...
US lawmakers seek probe into Nvidia CEO's ties with alleged Chinese spy amid national security concerns
US lawmakers from both parties are demanding investigations into reports that Nvidia CEO Jensen Huang had interactions with Alice Huang, an executive allegedly recruited by China's Ministry of State Security to gather information. The Trump administr...
Phase 4 studies show high satisfaction with facial treatments in adults on GLP-1 weight loss meds
Two Phase 4 studies, HARMONY IN DIVERSITY and HALO, found adults on GLP-1 medications for weight loss reported significant satisfaction improvements after receiving combined neurotoxin and hyaluronic acid (HA) injectable treatments. Participants note...
Intel stock halves despite record data center growth; future hinges on foundry progress and customer wins.
Intel's stock dropped over 50% recently despite posting its strongest data center growth in 15 years, reflecting concerns over heavy spending, foundry losses, and a weak PC market outlook for 2027. The company sees strong demand for server CPUs and A...
Wall Street sells AI stocks AMD and Palantir despite record growth; AMD favored for retirement portfolios due to valuation.
Despite both AMD and Palantir reporting record quarterly growth, their stock prices have fallen sharply due to concerns over high valuations, debt, and AI spending commitments. Palantir shows faster revenue growth but trades at extremely high multipl...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.